AU2021280285A1 - Formulations and methods for treating erectile dysfunction - Google Patents

Formulations and methods for treating erectile dysfunction Download PDF

Info

Publication number
AU2021280285A1
AU2021280285A1 AU2021280285A AU2021280285A AU2021280285A1 AU 2021280285 A1 AU2021280285 A1 AU 2021280285A1 AU 2021280285 A AU2021280285 A AU 2021280285A AU 2021280285 A AU2021280285 A AU 2021280285A AU 2021280285 A1 AU2021280285 A1 AU 2021280285A1
Authority
AU
Australia
Prior art keywords
vardenafil
formulation
organic
solubility
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021280285A
Other languages
English (en)
Inventor
Moses CHOW
Sheryl L. CHOW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Strategic Drug Solutions Inc
Original Assignee
Strategic Drug Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Strategic Drug Solutions Inc filed Critical Strategic Drug Solutions Inc
Publication of AU2021280285A1 publication Critical patent/AU2021280285A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021280285A 2020-05-26 2021-05-26 Formulations and methods for treating erectile dysfunction Pending AU2021280285A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063029881P 2020-05-26 2020-05-26
US63/029,881 2020-05-26
PCT/US2021/034334 WO2021242913A1 (en) 2020-05-26 2021-05-26 Formulations and methods for treating erectile dysfunction

Publications (1)

Publication Number Publication Date
AU2021280285A1 true AU2021280285A1 (en) 2023-02-02

Family

ID=78722740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021280285A Pending AU2021280285A1 (en) 2020-05-26 2021-05-26 Formulations and methods for treating erectile dysfunction

Country Status (10)

Country Link
US (1) US20240216383A1 (https=)
EP (1) EP4157449A4 (https=)
JP (1) JP2024521765A (https=)
KR (1) KR20240013128A (https=)
CN (1) CN116568289A (https=)
AU (1) AU2021280285A1 (https=)
BR (1) BR112022024098A2 (https=)
CA (1) CA3179630A1 (https=)
IL (1) IL298432A (https=)
WO (2) WO2021242913A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL247528B1 (pl) * 2023-04-08 2025-07-21 Sativa Med Spolka Akcyjna Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2391968A1 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
US20060207596A1 (en) * 2005-03-18 2006-09-21 Fairfield Clinical Trials, Llc Device and method for delivery of combination nasal medication
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
MX2010004265A (es) * 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
US20140271847A1 (en) * 2013-03-13 2014-09-18 SatisPharma, LLC Formulations and methods for rapid penile erections
US20170014417A1 (en) * 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
CN111655229A (zh) * 2017-12-20 2020-09-11 卡里亚制药控股有限公司 包含伐地那非的薄膜制剂、其制备方法及其用途
US11648197B2 (en) * 2018-06-28 2023-05-16 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs

Also Published As

Publication number Publication date
CA3179630A1 (en) 2021-12-02
WO2021242913A1 (en) 2021-12-02
IL298432A (en) 2023-01-01
EP4157449A1 (en) 2023-04-05
BR112022024098A2 (pt) 2023-02-07
WO2022250731A1 (en) 2022-12-01
JP2024521765A (ja) 2024-06-04
US20240216383A1 (en) 2024-07-04
KR20240013128A (ko) 2024-01-30
CN116568289A (zh) 2023-08-08
EP4157449A4 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
US12144808B2 (en) Compositions and methods
US8592406B2 (en) Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
ZA200307797B (en) Aripiprazole oral solution.
AU2021280285A1 (en) Formulations and methods for treating erectile dysfunction
CN101534804B (zh) 经鼻抗惊厥药物组合物
US12324811B2 (en) Intranasal formulation
US10874658B2 (en) Sublingual opioid formulations containing naloxone
Park et al. Can currently available drugs for erectile dysfunction be re-formulated to achieve rapid effect?
HK40098632A (zh) 治疗勃起功能障碍的配方和方法
US20240226086A1 (en) Liquid pharmaceutical formulations of quinolines
WO2017122161A1 (en) An intranasal composition comprising 5ht1b/1d receptor agonists
WO2026043819A1 (en) Formulations and methods for convenient and rapid diuresis for the treatment of edema
US20060193784A1 (en) Scopolamine sublingual spray for the treatment of motion sickness
AU2019358394B2 (en) Oromucosal solutions of Zolpidem or pharmaceutically acceptable salts thereof
WO2026062705A1 (en) Oromucosal liquid compositions of betahistine or its pharmaceutically acceptable salt(s) and processes for preparation thereof
PL247528B1 (pl) Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji
WO2022123433A1 (en) Oral pharmaceutical compositions of remdesivir
EA045748B1 (ru) Раствор золпидема или его фармацевтически приемлемой соли для оромукозного введения для лечения бессонницы